Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin s Alticor Alliance Nets a Distribution Deal and $2M Cash

NEW YORK, March 16 (GenomeWeb News) - Building on a year-old partnership with Alticor, the parent company of Amway, Interleukin Genetics today said it has signed a distribution agreement for its genetic tests with another Alticor subsidiary to secure an additional $2 million in capital.

Interleukin signed a distribution agreement for its DNA-based risk assessment tests with Access Business Group International LLC, a subsidiary of Alticor that engages in "development, sourcing, manufacture, and distribution of Amway-branded products," according to the Access Business Group website.

This agreement is considered a "milestone" under a strategic alliance that Interleukin and Alticor initiated last March, under which Interleukin received equity funding of around $16 million in stock, credit, and cash.

According to Interleukin, the criteria for the the milestone required that it enter into a genetic testing agreement "with one or more customers of such size that the projected internal rate of return with respect to the project is at least 20 percent with a payback period of three years or less."

The distribution agreement will net Interleukin an additional $2 million capital contribution from Alticor with no additional shares being issued to Alticor.

Interleukin said it is planning to launch a genetic testing product next year.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.